The Technical Analyst
Treace Medical Concepts, [TMCI]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Treace Medical Concepts, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-3.03% $11.52
America/New_York / 16 apr 2024 @ 14:11
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 711.42 mill |
| EPS: | -0.810 |
| P/E: | -14.22 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 61.76 mill |
| Avg Daily Volume: | 0.426 mill |
| RATING 2024-04-16 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -14.22 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.06x |
| Company: PE -14.22 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 10.92 - 12.12 ( +/- 5.21%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-11-15 | Treace James T | Sell | 46 500 | Common Stock |
| 2022-11-15 | Treace James T | Sell | 1 600 | Common Stock |
| 2022-11-15 | Treace James T | Sell | 200 | Common Stock |
| 2022-11-15 | Treace James T | Sell | 1 700 | Common Stock |
| 2024-03-08 | Berutti Aaron | Sell | 711 | Common Stock |
| INSIDER POWER |
|---|
| -1.16 |
| Last 99 transactions |
| Buy: 1 598 706 | Sell: 2 048 382 |
Forecast:
15:50 - $11.51
Live Trading Signals (every 1 min)
Forecast
1: 14:20 - $11.51
Forecast 2: 15:10 - $11.42
Forecast 3: 15:50 - $11.51
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $11.52 (-3.03% ) |
| Volume | 0.121 mill |
| Avg. Vol. | 0.426 mill |
| % of Avg. Vol | 28.36 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TMCI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $15.00 | N/A | Active |
|---|
TMCI
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
Latest Press Releases
2024-04-16 07:00:00 - Press Release
Treace Announces First Annual National Bunion Day
Focus on foot health issue affecting millions of people includes outreach and education efforts to build awareness, reduce stigma and correct misconceptions about this common bone deformity focus on foot health issue affecting millions of people includes outreach and education efforts to build awareness, reduce stigma and correct misconceptions about this common bone deformity
2024-04-09 07:00:00 - Press Release
Treace To Report First Quarter 2024 Financial Results
Company to host conference call on tuesday, may 7, 2024 at 4:30 pm et company to host conference call on tuesday, may 7, 2024 at 4:30 pm et
2024-03-25 07:00:00 - Press Release
Treace Celebrates 100,000 Lapiplasty® 3d Bunion Correction® Patient Milestone
Treace further expands focus on bunion deformity education by sponsoring first-ever national bunion day in the u.s. on april 16, 2024
2024-02-27 16:05:00 - Press Release
Treace Medical Concepts Reports Fourth Quarter And Full-year 2023 Financial Results And Provides 2024 Guidance
Ponte vedra, fla., feb. 27, 2024 (globe newswire) -- treace medical concepts, inc. (“treace” or the “company”) (nasdaqgs: tmci), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship lapiplasty ® and adductoplasty ® procedures, today reported financial results for the fourth quarter and full year ended december 31, 2023 and provided 2024 guidance.
2024-02-07 16:05:00 - Press Release
Treace To Report Fourth Quarter And Full-year 2023 Financial Results
Company to host conference call on tuesday, february 27, 2024 at 4:30 pm et company to host conference call on tuesday, february 27, 2024 at 4:30 pm et
Latest News
2024-04-15 09:45:30 - InvestorPlace
7 Stable Stocks for 50% Returns by Early 2025
Investors who seek 50% returns in less than 12 months generally will have many choices within stable stocks. The general maxim regarding risk and return applies here: Risky, unstable stocks tend to offer much higher return potential.
2024-04-09 07:00:00 - GlobeNewsWire
Treace to Report First Quarter 2024 Financial Results
Company to Host Conference Call on Tuesday, May 7, 2024 at 4:30 pm ET Company to Host Conference Call on Tuesday, May 7, 2024 at 4:30 pm ET
2024-02-28 21:14:08 - Seeking Alpha
Treace Medical Concepts Inc (TMCI) Q4 2023 Earnings Call Transcript
2024-02-27 19:36:05 - Zacks Investment Research
Treace Medical Concepts (TMCI) Reports Q4 Loss, Tops Revenue Estimates
Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.
2024-02-07 16:05:00 - GlobeNewsWire
Treace to Report Fourth Quarter and Full-Year 2023 Financial Results
Company to Host Conference Call on Tuesday, February 27, 2024 at 4:30 pm ET Company to Host Conference Call on Tuesday, February 27, 2024 at 4:30 pm ET
2023-12-19 07:00:00 - GlobeNewsWire
Treace to Present at 42nd Annual J.P. Morgan Healthcare Conference
PONTE VEDRA, Fla., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T.
2023-11-11 15:42:09 - Seeking Alpha
Treace Medical Concepts, Inc. (TMCI) Q3 2023 Earnings Call Transcript
Treace Medical Concepts, Inc. (NASDAQ:TMCI ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Julie Dewey - Chief Communications & Investor Relations Officer John Treace - Chief Executive Officer Mark Hair - Chief Financial Officer Conference Call Participants Danielle Antalffy - UBS Lilia-Celine Lozada - JPMorgan Richard Newitter - Truist Securities Rick Wise - Stifel Andrew Ranieri - Morgan Stanley Ryan Zimmerman - BTIG George Sellers - Stephens Inc. Operator Good day and thank you for standing by. Welcome to Treace Medical Concepts Third Quarter 2023 Earnings Conference Call.
2023-10-30 07:00:00 - GlobeNewsWire
Treace to Present at Stifel 2023 Healthcare Conference
PONTE VEDRA, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023, beginning at approximately 8:35 am ET.
2023-10-27 12:09:08 - Seeking Alpha
Treace Medical Concepts Continues Growth Investments Despite High Operating Losses
Treace Medical Concepts, Inc. sells medical device treatments for foot bunions. The global market for bunion correction systems is forecasted to reach $1.25 billion by 2030. Treace Medical's financial trends have shown rising revenue but continued substantial operating losses.
2023-10-16 07:00:00 - GlobeNewsWire
Treace to Report Third Quarter 2023 Financial Results
Company to Host Conference Call on Thursday, November 9, 2023 at 4:30 pm ET Company to Host Conference Call on Thursday, November 9, 2023 at 4:30 pm ET